M2S is a provider of medical technology derived from 3D imaging for specialties in which precise and accurate anatomical calculations are vital to patients' well-being and treatment. The Company focuses on all aspects of a treatment cycle - pre-operative planning, intra-operative guidance, post-operative evaluation, and long-term continued care - across many medical specialties. M2S provides technology and services to the healthcare industry to manage clinical information, reduce costs, and improve the quality of patient care.
M2S has filed 14 patents.
Ophthalmology, Diseases of the eye and adnexa, Vision, Optometry, Eye procedures
Ophthalmology, Diseases of the eye and adnexa, Vision, Optometry, Eye procedures
Latest M2S News
May 26, 2023
News Provided By Share This Article The Stealth Electric Bike, shown here, is a great electric bike option for urban riding and commuting. The Stealth HT Electric Commuter bike is currently available for $1199 - a 33% savings on standard pricing - for a limited time through our crowdfunding campaign. Revolutionize your daily commute with the fast and powerful Stealth Electric Commuter Bike by M2S Bikes. Commuting can be a chore, but it doesn't have to be. That's why we designed the Stealth Electric Commuter Bike – to turn your daily commute into the best part of your day.” — Eric Crews, founder of M2S Bikes ASHEVILLE, NORTH CAROLINA, UNITED STATES, May 26, 2023/ EINPresswire.com / -- As urban traffic continues to worsen, M2S Bikes has launched the Stealth Electric Commuter Bike to provide a greener, healthier, and more enjoyable way to commute. With its powerful motor, long-lasting battery, and rugged design, this e-bike is ideal for tackling any urban landscape. And at $1199 during the campaign, it's a great value for anyone looking for a high-quality e-bike. The Stealth Electric Commuter Bike boasts a top speed of 20 mph on throttle only, and up to 28 mph when the throttle is removed. Its fully integrated 615 watt-hour battery provides 20 to 50 miles of range per charge, enabling riders to tackle long commutes with ease. The bike also comes with optional full coverage fenders and a rear rack with LED tail light, making it suitable for all weather conditions. But the Stealth Electric Commuter Bike is not just about power – it also offers comfort and convenience. With pedal-assist technology and a responsive 8-Speed Shimano Drivetrain, riders can enjoy effortless shifting while receiving exercise benefits similar to a traditional bike. The bike is also equipped with hydraulic disc brakes for quick and safe stops. M2S Bikes is offering an exclusive opportunity for Test Ride Ambassadors to receive the Stealth at a special discounted price in exchange for sharing their experiences and honest reviews onsocial media. Additionally, pricing and pre-order options are available for the Stealth Electric Commuter Bike. Customers can reserve their bike for just $199 and pay the remaining $1,000 balance before shipping. For those who missed out on the first wave of in-stock bikes, pre-order options are available for bikes that are ready to ship from M2S Bikes' manufacturing partner in Asia, with an additional $100 off during the campaign. According to M2S Bikes' founder, Eric Crews, "We designed the Stealth Electric Commuter Bike to revolutionize daily commutes and turn them into a more enjoyable experience. With our innovative design and engineering, quality and craftsmanship, customization options, and eco-friendly and sustainable practices, M2S Bikes is committed to a greener, healthier future." Join the e-bike movement today and experience the Stealth Electric Commuter Bike by M2S Bikes. With over 160 bikes in stock at their Asheville, NC warehouse, it's a great opportunity to get your hands on a high-quality e-bike while supplies last. Eric Crews
M2S Frequently Asked Questions (FAQ)
When was M2S founded?
M2S was founded in 1998.
Where is M2S's headquarters?
M2S's headquarters is located at 12 Commerce Avenue, West Lebanon.
What is M2S's latest funding round?
M2S's latest funding round is Acquired - II.
How much did M2S raise?
M2S raised a total of $3.5M.
Who are the investors of M2S?
Investors of M2S include Medstreaming, Altaris Capital Partners, Village Ventures, Peninsula Ventures, Commons Capital and 7 more.
Who are M2S's competitors?
Competitors of M2S include Natus Medical, Optovue, Redlen Technologies, Decipher Biosciences, Novadaq Technologies and 7 more.
Compare M2S to Competitors
Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.
Optasia Medical aims to build medical imaging-based Computer Assisted Detection (CAD) solutions to help physicians make better decisions. With Optasia Medical's tools, medical images can be evaluated more rapidly, more accurately and more reproducibly. The Optasia platform aims to enable robust model-based vision solutions to automated medical image interpretation problems. With Optasia, new applications can be developed rapidly for seamless integration into the clinical workflow.nOptasia Medical is applying the Optasia platform to problems in musculoskeletal disease. Specifically, for the analysis of X-ray images in the detection and monitoring of osteoporosis, osteoarthritis and rheumatoid arthritis and the planning and assessment of orthopedic surgery
NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.
Binx Health is a healthcare company focused on point-of-care molecular diagnostics. The company offers diagnostic solutions that enable healthcare providers to deliver timely, high-quality care, including a testing platform for the diagnosis and treatment of chlamydia and gonorrhea infections. Binx Health primarily serves the healthcare industry. Binx Health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Tympany is developing automated, hearing, diagnostic technology. Tympany aims to improve early detection of hearing loss, increase access to diagnostics, and facilitate the ease and convenience of personalized treatment. The company is located in The Woodlands, Texas, with regional offices throughout the U.S